Lexapro® (Escitalopram Oxalate Tablets) is indicated for the treatment of Major Depressive Disorder (MDD) panic disorder with or without agoraphobia. Lexapro® was launched in Europe in 2002 and in China in 2006. Due to the upgrade of molecular structure, Lexapro® has fewer side effects1 and greater antidepressant and anxiolytic efficacy.2 Compared with other antidepressant, it has achieved better clinical efficacy3 and safety balance. A number of existing clinical data proves that Lexapro® can improve the core
symptoms in a quick and sustainable manner, reduce the risk of suicide, relieve suicidal symptoms, and effectively prevent the relapse of depression. In clinical guidelines for depressive disorders in countries like US, Canada, UK, etc., Lexapro® has been recommended as the ﬁrst-line antidepressant with better efficacy, safety and health economics data.
1. Alzheimer Disease International. World Alzheimer Report 2015. The benefits of early diagnosis and intervention. Published by Alzheimer’s Disease International (ADI), September 2015
2. Rössler W, Salize HJ, van Os J, Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005; 15 (4): 399_409, Lindström E, Eberhard J, Neovius M, Levander S. Costs of schizophrenia during 5 years. Acta Psychiatr Scand Suppl 2007; 116 (435): 33_40.
3. http://www.who.int/mediacentre/factsheets/fs397/en/ (December 2016).